Skip to main content
Log in

Metabolic disturbances in diabetic cardiomyopathy

  • Published:
Molecular and Cellular Biochemistry Aims and scope Submit manuscript

Abstract

It has been established that diabetes results in a cardiomyopathy, and increasing evidence suggests that an altered substrate supply and utilization by cardiac myocytes could be the primary injury in the pathogenesis of this specific heart muscle disease. For example, in diabetes, glucose utilization is insignificant, and energy production is shifted almost exclusively towards β-oxidation of free fatty acids (FFA). FFA's are supplied to cardiac cells from two sources: lipolysis of endogenous cardiac triglyceride (TG) stores, or from exogenous sources in the blood (as free acid bound to albumin or as TG in lipoproteins). The approximate contribution of FFA from exogenous or endogenous sources towards β-oxidation in the diabetic heart is unknown. In an insulin-deficient state, adipose tissue lipolysis is enhanced, resulting in an elevated circulating FFA. In addition, hydrolysis of the augmented myocardial TG stores could also lead to high tissue FFA. Whatever the source of FFA, their increased utilization may have deleterious effects on myocardial function and includes the abnormally high oxygen requirement during FFA metabolism, the intracellular accumulation of potentially toxic intermediates of FFA, a FFA-induced inhibition of glucose oxidation, and severe morphological changes. Therapies that target these metabolic aberrations in the heart during the early stages of diabetes could potentially delay or impede the progression of more permanent sequelae that could ensue from otherwise uncontrolled derangements in cardiac metabolism.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Palumbo PJ, Elveback CR, Conolly DC: Coronary artery disease and congestive heart failure in the diabetic: Epidemiological aspects. The Rochester Diabetes Project. In: RC Scott (ed). Clinical Cardiology and Diabetes. Futura, New York, 1981, p 13

    Google Scholar 

  2. Kannel WB, McGee DL: Diabetes and cardiovascular disease: The Framingham Study. JAMA 229: 1749–1754, 1974

    Google Scholar 

  3. Ledet B, Neubauer B, Christnesen NJ, Lundback K: Diabetic cardiopathy. Diabetologia 16: 207–209, 1979

    Google Scholar 

  4. Hamby RI, Zoneraich S, Sherman L: Diabetic cardiomyopathy. JAMA 229: 1749–1754, 1974

    Google Scholar 

  5. Regan TJ, Lyons MM, Ahmed SS: Evidence for cardiomyopathy in familial diabetes mellitus. J Clin Invest 60: 885–889, 1977

    Google Scholar 

  6. Miller TB Jr: Cardiac performance of isolated perfused hearts from alloxan diabetic rats. Am J Physiol 236: 808–812, 1979

    Google Scholar 

  7. Fein FS, Sonnenblick EH: Diabetic cardiomyopathy. Prog Cardiovasc Res 27: 255–270, 1985

    Google Scholar 

  8. Vadlamudi RVSV, Rodgers RL, McNeill JH: The effect of chronic alloxan-and streptozotocin-induced diabetes on isolated rat heart performance. Can J Physiol Pharmacol 60: 902–911, 1982

    Google Scholar 

  9. Rodrigues B, McNeill JH: The diabetic heart: Metabolic causes for the development of a cardiomyopathy. Cardiovasc Res 26: 913–992, 1992

    Google Scholar 

  10. Rodrigues B, Cam MC, McNeill JH: Myocardial substrate metabolism: Implications for diabetic cardiomyopathy. J Mol Cell Cardiol 27: 169–179, 1995

    Google Scholar 

  11. Gibbons GF: Assembly and secretion of hepatic very-low-density lipoprotein. Biochem J 268: 1–13, 1990

    Google Scholar 

  12. Rodrigues B, Grassby PF, Battell ML, Lee SYN, McNeill JH: Hypertriglyceridemia in experimental diabetes: Relationship to cardiac dysfunction. Can J Physiol Pharmacol 72: 447–455, 1994

    Google Scholar 

  13. Mamo JCL, Hirano T, Sainsbury A, Fitzgerald AK, Redgrave TG: Hypertriglyceridemia is exacerbated by slow lipolysis of triacylglycerol-rich lipoproteins in fed but not fasted streptozotocin diabetic rats. Biochim Biophys Acta 1128: 132–138, 1992

    Google Scholar 

  14. Kannel WB, McGee DL: Diabetes and cardiovascular risk factors. The Framingham Study. Circulation 59: 8–13, 1979

    Google Scholar 

  15. West KM, Ahuja MMS, Bennett PH, Czyzyk A, Mateo de Acosta O, Fuller JH, Grab B, Grabauskas V, Jarrett RJ, Kosaka K, Keen H, Krolewski AS, Miki E, Schliack V, Teuscher A, Watkins PJ, Strober JA: The role of circulating glucose and triglyceride concentrations and their interactions with other ‘risk factors’ as determinants of arterial disease in nine diabetic population samples from the WHO Multi National study. Diabetes Care 6: 361–369, 1983

    Google Scholar 

  16. Rodrigues B, Xiang H, McNeill JH: Effects of L-carnitine treatment on lipid metabolism and cardiac performance in chronically diabetic rats. Diabetes 37: 1358–1364, 1988

    Google Scholar 

  17. Rodrigues B, Goyal RK, McNeil1 JH: Effects of hydralazine on streptozotocin-induced diabetic rats: Prevention of hyperlipidemia and improvement in cardiac function. J Pharmacol ExpTher 237: 292–299, 1986

    Google Scholar 

  18. McNeill JH, Rodrigues B: Heart function in WKY diabetic rats. J Mol Cell Cardiol 28(6): A202, 1996

    Google Scholar 

  19. Denton RM, Randle PJ: Concentration of glycerides and phospholipids in rat heart and gastronemius muscles. Effects of alloxan-diabetes and perfusion. Biochem J 104: 416–422, 1967

    Google Scholar 

  20. Kenno KA, Severson DL: Lipolysis in isolated myocardial cells from diabetic rat hearts. Am J Physiol 249: 1024–1030, 1985

    Google Scholar 

  21. Chattopadhyay J, Thompson EW, Schmid HHO: Elevated levels of nonesterified fatty acids in the myocardium of alloxan diabetic rats. Lipids 25: 307–310, 1990

    Google Scholar 

  22. Eckel RH: Lipoprotein lipase. A multifunctional enzyme relevant to common metabolic diseases. N Engl J Med 320: 1060–1068, 1989

    Google Scholar 

  23. O'Brien KD, Ferguson M, Gordon D, Deeb SS, Chait A: Lipoprotein lipase is produced by cardiac myocytes rather than interstitial cells in human myocardium. Arterioscler Thromb 14: 1445–1451, 1994

    Google Scholar 

  24. Hamosh M, Hamosh P: Lipoprotein lipase: Its physiological and clinical significance. Mol Aspects Med 6: 199–289, 1983

    Google Scholar 

  25. Elkeles RS, Hambley J: The effects of fasting and streptozotocin on hepatic triglyceride lipase activity in the rat. Diabetes 26: 58–60, 1977

    Google Scholar 

  26. Veeraraghavan K, Murthy K, Bauman MD, Shipp J: Regulation of triacylglycerol lipolysis in the perfused hearts of normal and diabetic rats. Diabetes 32: 718–722, 1983

    Google Scholar 

  27. Nomura T, Hagino H, Gotoh M, Iguchi A, Sakamoto N: The effects of streptozotocin diabetes on tissue specific lipase activities in the rat. Lipids 19: 594–599, 1984

    Google Scholar 

  28. Tavangar K, Murata Y, Pedersen ME, Goers JF, Hoffman AR, Kraemer FB: Regulation of lipoprotein lipase in the diabetic rat. J Clin Invest 90: 1672–1678, 1992

    Google Scholar 

  29. O'Looney P, Maten MV, Vahouny GV: Insulin-mediated modifications of myocardial lipoprotein lipase and lipoprotein metabolism. J Biol Chem 258: 12994–13001, 1983

    Google Scholar 

  30. Braun JEA, Severson DL: Lipoprotein lipase release from cardiac myocytes is increased by decavanadate but not insulin. Am J Physiol 262: 663–670, 1992

    Google Scholar 

  31. Rodrigues B, Severson DL: Acute diabetes does not reduce heparin-releasable lipoprotein lipase activity in perfused hearts from Wistar-Kyoto rats. Can J Physiol Pharmacol 71: 657–661, 1993

    Google Scholar 

  32. Mamo JCL, Hirano T, Sainsbury A, Fitzgerald AK, Redgrave TG: Hypertriglyceridemia is exacerbated by slow lipolysis of triacylglycerol-rich lipoproteins in fed but not fasted streptozotocin diabetic rats. Biochim Biophys Acta 1128: 132–138, 1992

    Google Scholar 

  33. Rutledge JC, Goldberg IJ: Lipoprotein lipase (LpL) affects low density lipoprotein (LDL) flux through vascular tissue: Evidence that LpL increases LDL accumulation in vascular tissue. J Lipid Res 35: 1152–1160, 1994

    Google Scholar 

  34. Fernandez-Borja M, Bellido D, Vilella E, Olivecrona G, Vilaro S: Lipoprotein lipase-mediated uptake of lipoprotein in human fibroblasts: Evidence for an LDL receptor-independent internalization pathway. J Lipid Res 37: 464–481, 1996

    Google Scholar 

  35. Tsutsumi K, Inoue Y, Shina A, Murase T: Correction of hypertiglyceridemia with low high-density lipoprotein cholesterol by the novel compound NO-1886, a lipoprotein lipase promoting agent, in STZ-induced diabetic rats. Diabetes 44: 414–417, 1995

    Google Scholar 

  36. Liu K, Pierce GN: The effects of low density lipoprotein on Ca2+ transients in isolated rabbit cardiomyocytes. J Biol Chem 268: 3767–3775, 1993

    Google Scholar 

  37. DeFronzo RA, Jacot E, Jequier E, Maeder E, Wahren J, Felber JP: The effect of insulin on the disposal of intravenous glucose: Results from indirect calorimetry and hepatic and femoral venous catheterization. Diabetes 30: 1000–1007, 1981

    Google Scholar 

  38. Cushman SW, Wardzala LJ: Potential mechanism of insulin action on glucose transport in the isolated rat adipose cell. Apparent translocation of intracellular transport systems to the plasma membrane. J Biol Chem 255: 4758–4762, 1980

    Google Scholar 

  39. Karnieli E, Zarnowski MJ, Hissin PJ, Simpson IA, Salans LB, Cushman SW: Insulin-stimulated translocation of glucose transport systems in the isolated rat adipose cell. J Biol Chem 256: 4772–4777, 1981

    Google Scholar 

  40. Chen V, Ianuzzo CD, Fong BC, Spitzer JJ: The effects of acute and chronic diabetes on myocardial metabolism in rats. Diabetes 33: 1078–1084, 1984

    Google Scholar 

  41. Eckel J, Reinauer H: Insulin action on glucose transport in isolated cardiac myocytes: Signalling pathways and diabetes induced alterations. Biochem Soc Trans 18: 1135–1137, 1990

    Google Scholar 

  42. Garvey WG, Hardin D, Juhaszova M, Dominguez JH: Effects of diabetes on myocardial glucose transport system in rats: implication for diabetic cardiomyopathy. Am J Physiol 264: 837–844, 1993

    Google Scholar 

  43. Randle PJ, Hales CN, Garland PB, Newsholme EA: The glucose fatty acid cycle: Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1: 785–789, 1963

    Google Scholar 

  44. Chen V, Ianuzzo CD: Dosage effect of streptozotocin on rat tissue enzyme activities and glycogen concentration. Can J Physiol Pharmacol 60: 1251–1256, 1982

    Google Scholar 

  45. Kerbey AK, Vary TC, Randle PJ: Molecular mechanisms regulating myocardial glucose oxidation. Basic Res Cardiol 80 (suppl 2): 93–96, 1985

    Google Scholar 

  46. Wieland O, Siess E, Schulze-Wethmar FH, van Funcke HG, Winton B: Active and inactive forms of pyruvate dehydrogenase in rat heart and kidney: Effects of diabetes, fasting and refeeding on pyruvate dehydrogenase interconversion. Arch Biochem Biophys 143: 593–601, 1971

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rodrigues, B., Cam, M.C. & McNeill, J.H. Metabolic disturbances in diabetic cardiomyopathy. Mol Cell Biochem 180, 53–57 (1998). https://doi.org/10.1023/A:1006882805197

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006882805197

Navigation